Cidara Therapeutics Inc (CDTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cidara Therapeutics Inc (CDTX) has a cash flow conversion efficiency ratio of -0.096x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.62 Million) by net assets ($422.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CDTX company net worth for the company's overall valuation and market capitalisation.
Cidara Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Cidara Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cidara Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cidara Therapeutics Inc ranked by their cash flow conversion efficiency. Explore CDTX operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Quebecor Inc
TO:QBR-B
|
0.150x |
|
Sibanye Stillwater Ltd
JSE:SSW
|
0.194x |
|
New Gold Inc
TO:NGD
|
0.175x |
|
OneMain Holdings Inc
NYSE:OMF
|
0.455x |
|
RATIONAL UN.ADR 1/ 1/20
F:RAA1
|
0.096x |
|
SODEXO S.A. ADR/ 1/5 EO 4
F:SJ70
|
N/A |
|
ISS A/S
CO:ISS
|
0.070x |
|
Sandfire Resources Ltd
AU:SFR
|
0.294x |
Annual Cash Flow Conversion Efficiency for Cidara Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Cidara Therapeutics Inc from 2013 to 2024. View Cidara Therapeutics Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $163.31 Million | $-176.53 Million | -1.081x | -139.56% |
| 2023-12-31 | $-8.21 Million | $-22.43 Million | 2.732x | +38.55% |
| 2022-12-31 | $-14.44 Million | $-28.47 Million | 1.972x | +268.61% |
| 2021-12-31 | $21.57 Million | $-25.23 Million | -1.170x | +76.97% |
| 2020-12-31 | $10.71 Million | $-54.41 Million | -5.078x | -573.37% |
| 2019-12-31 | $37.84 Million | $-28.53 Million | -0.754x | +21.35% |
| 2018-12-31 | $59.14 Million | $-56.70 Million | -0.959x | -14.78% |
| 2017-12-31 | $59.74 Million | $-49.91 Million | -0.835x | -85.22% |
| 2016-12-31 | $88.18 Million | $-39.77 Million | -0.451x | -80.54% |
| 2015-12-31 | $103.91 Million | $-25.96 Million | -0.250x | +31.62% |
| 2014-12-31 | $21.10 Million | $-7.71 Million | -0.365x | -148.74% |
| 2013-12-31 | $-1.40 Million | $-1.05 Million | 0.750x | -- |
About Cidara Therapeutics Inc
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are funga… Read more